Search results
Showing 1 to 4 of 4 results for anakinra rheumatoid arthritis
This guideline covers diagnosing and managing rheumatoid arthritis. It aims to improve quality of life by ensuring that people with rheumatoid arthritis have the right treatment to slow the progression of their condition and control their symptoms. People should also have rapid access to specialist care if their condition suddenly worsens.
Past technology appraisal appeals and decisions
The clinical effectiveness and cost effectiveness of anakinra for rheumatoid arthritis (TA72)
This appraisal has been updated and replaced by NICE guideline CG79.
Evidence-based recommendations on adalimumab (Humira), certolizumab pegol (Cimzia), etanercept (Enbrel), golimumab (Simponi) and infliximab (Remicade, Remsima, Inflectra). These drugs are for people with active ankylosing spondylitis or non-radiographic axial spondyloarthritis .